Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab ...

Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug ...

Evotec has received a US$5m milestone payment from Bristol Myers Squibb following the US Food and Drug Administration’s ...

Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR ...

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...

With a favourable safety profile and consistent activity across tumour types, agenT-797 is now poised to enter phase 2 trials. MiNK believes the therapy could redefine treatment for patients with ...

Gastro-resistant mercaptamine, marketed as Procysbi, has been accepted for use within NHS Scotland for the treatment of nephropathic cystinosis – a rare, progressive and life-limiting condition ...

2025 is not just another year in pharma – it’s a turning point. The industry is riding a wave of scientific breakthroughs, regulatory agility and patient-centric innovation that’s reshaping the very ...

Rebuilding the clinical trials landscape in the UK ...

Women’s health issues have historically been under-researched, marginalised and underserved. This systemic neglect has led to ...